Pancreatic Cancer Research

ResearcherGifu University HospitalActive in the last 2 years

Shinya Uemura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3283-1680; OpenAlex author ID A5103197965. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 5 papers · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 18

  1. 11.5-Fr Large-Bore Plastic Stents Versus Fully Covered Self-Expandable Metallic Stents for the Management of Preoperative Endoscopic Biliary Obstruction in Pan… Co-author DOI 10.1007/s10620-026-10136-z↗
  2. Early elemental diet supplementation during chemotherapy improves treatment response and survival in advanced pancreatic cancer: A single-center randomized con… Co-author DOI 10.1016/j.clnesp.2026.103106↗
  3. Assessment of safety and patency of 7-mm covered metal stents for preoperative biliary drainage in pancreatic cancer: Prospective multicenter study. Co-author DOI 10.1055/a-2503-1995↗
  4. Development of Pancreatic Cancer during the Follow-up of Autoimmune Pancreatitis: A Report of Two Cases. Co-author DOI 10.2169/internalmedicine.2086-23↗
  5. Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective … Co-author DOI 10.1007/s00520-023-08136-0↗
  6. Impact of Controlling nutritional status (CONUT) in patients with unresectable advanced pancreatic cancer receiving multi-agent chemotherapy: A single center, … Co-author DOI 10.1016/j.pan.2022.01.010↗
  7. The efficacy and safety of modified FOLFIRINOX for unresectable advanced pancreatic cancer in elderly versus young patients: A multicenter retrospective cohort… Co-author DOI 10.1016/j.pan.2022.11.005↗
  8. Covered self-expandable metallic stent versus plastic stent for preoperative endoscopic biliary drainage in patients with pancreatic cancer: a multi-center ret… Co-author DOI 10.1080/00365521.2021.2015802↗
  9. Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer. Co-author DOI 10.3390/jcm11195895↗
  10. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Co-author DOI 10.1017/s0007114520003463↗
  11. Evaluation of preoperative diagnostic methods for resectable pancreatic cancer: a diagnostic capability and impact on the prognosis of endoscopic ultrasound-gu… Co-author DOI 10.1186/s12876-021-01955-7↗
  12. Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient che… Co-author DOI 10.1186/s40780-021-00210-1↗
  13. Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients… Co-author DOI 10.21873/anticanres.15154↗
  14. Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Cen… Co-author DOI 10.3390/jcm10132848↗
  15. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. Co-author DOI 10.3390/jcm8060761↗
  16. Endoscopic duodenal stent versus surgical gastrojejunostomy for gastric outlet obstruction in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.04.015↗
  17. Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy. Co-author DOI 10.3390/cancers10110454↗
  18. A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.22795↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takuji Iwashita · 18 shared papers, 2017–2026 · strength 2.87
  2. Masahito Shimizu · 17 shared papers, 2017–2026 · strength 2.64
  3. Hironao Ichikawa · 6 shared papers, 2021–2026 · strength 1.11
  4. Akinori Maruta · 6 shared papers, 2017–2026 · strength 1.08
  5. Naoki Mita · 5 shared papers, 2019–2026 · strength 0.82
  6. Koichi Ohata · 5 shared papers, 2018–2023 · strength 0.67
  7. Akio Suzuki · 5 shared papers, 2018–2023 · strength 0.67
  8. Kensaku Yoshida · 5 shared papers, 2017–2022 · strength 0.61
  9. Shiori Sadaka · 4 shared papers, 2021–2023 · strength 0.59
  10. Ryuichi Tezuka · 3 shared papers, 2022–2024 · strength 0.55
  11. Mitsuru Okuno · 4 shared papers, 2017–2026 · strength 0.55
  12. Hironori Fujii · 4 shared papers, 2018–2022 · strength 0.48
  13. Ichiro Yasuda · 3 shared papers, 2018–2022 · strength 0.37
  14. Fumitaka Niiya · 1 shared paper, 2025 · strength 0.22
  15. Keita P. Mori · 1 shared paper, 2025 · strength 0.22
  16. Hirotoshi Ishiwatari · 1 shared paper, 2025 · strength 0.22
  17. Junya Sato · 1 shared paper, 2025 · strength 0.22
  18. Shinya Endo · 1 shared paper, 2025 · strength 0.22
  19. Shinya Kawaguchi · 1 shared paper, 2025 · strength 0.22
  20. Tatsunori Satoh · 1 shared paper, 2025 · strength 0.22
  21. Yunami Yamada · 1 shared paper, 2018 · strength 0.08
  22. Junji Kawaguchi · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.